KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Long Term Investments

Last Annual Value

499.00K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

KT

Kalaris Therapeutics Inc Competitors Analysis of Long Term Investments

KLRS · NASDAQ
CompanyLong Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
499.00K
N/A-10.1%N/A 
64.70M
54.3%78.6%N/A
0.00
N/AN/AN/A
1.00M
N/AN/AN/A
0.00
N/AN/AN/A
2.15M
-48.7%-19.6%N/A
0.00
N/AN/AN/A
3.49M
-53.8%N/AN/A
4.25M
0.0%N/AN/A
36.00K
N/A-74.4%N/A
93.74M
18.5%69.5%23.3%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7